RSLS Stock Overview
Provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ReShape Lifesciences Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.18 |
52 Week High | US$2.70 |
52 Week Low | US$0.14 |
Beta | 1.28 |
1 Month Change | 7.07% |
3 Month Change | 12.11% |
1 Year Change | -93.07% |
3 Year Change | -99.94% |
5 Year Change | -99.96% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)
Apr 18ReShape wins FDA clearance for device used in weight loss surgery
Aug 10Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results
Mar 31Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?
Dec 09Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?
Aug 24Shareholder Returns
RSLS | US Medical Equipment | US Market | |
---|---|---|---|
7D | 2.7% | 1.1% | 1.2% |
1Y | -93.1% | 4.2% | 27.7% |
Return vs Industry: RSLS underperformed the US Medical Equipment industry which returned 4.2% over the past year.
Return vs Market: RSLS underperformed the US Market which returned 27.7% over the past year.
Price Volatility
RSLS volatility | |
---|---|
RSLS Average Weekly Movement | 10.9% |
Medical Equipment Industry Average Movement | 8.3% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.2% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: RSLS has not had significant price volatility in the past 3 months.
Volatility Over Time: RSLS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 29 | Paul Hickey | www.reshapelifesciences.com |
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual’s comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus.
ReShape Lifesciences Inc. Fundamentals Summary
RSLS fundamental statistics | |
---|---|
Market cap | US$4.34m |
Earnings (TTM) | -US$10.92m |
Revenue (TTM) | US$8.34m |
0.5x
P/S Ratio-0.4x
P/E RatioIs RSLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RSLS income statement (TTM) | |
---|---|
Revenue | US$8.34m |
Cost of Revenue | US$2.85m |
Gross Profit | US$5.49m |
Other Expenses | US$16.41m |
Earnings | -US$10.92m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.47 |
Gross Margin | 65.85% |
Net Profit Margin | -130.99% |
Debt/Equity Ratio | 0% |
How did RSLS perform over the long term?
See historical performance and comparison